CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Galera Therapeutics, Inc. - GRTX CFD

0.1666
1.77%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0127
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Galera Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 0.1696
Open* 0.1655
1-Year Change* -89.85%
Day's Range* 0.1613 - 0.168
52 wk Range 0.20-3.59
Average Volume (10 days) 1.43M
Average Volume (3 months) 52.63M
Market Cap 8.95M
P/E Ratio -100.00K
Shares Outstanding 43.93M
Revenue N/A
EPS -2.16
Dividend (Yield %) N/A
Beta 1.90
Next Earnings Date Nov 7, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Oct 2, 2023 0.1666 -0.0001 -0.06% 0.1667 0.1682 0.1607
Sep 29, 2023 0.1696 0.0001 0.06% 0.1695 0.1765 0.1658
Sep 28, 2023 0.1748 0.0003 0.17% 0.1745 0.1777 0.1678
Sep 27, 2023 0.1727 -0.0025 -1.43% 0.1752 0.1856 0.1670
Sep 26, 2023 0.1749 0.0039 2.28% 0.1710 0.1774 0.1694
Sep 25, 2023 0.1678 -0.0013 -0.77% 0.1691 0.1710 0.1597
Sep 22, 2023 0.1715 0.0014 0.82% 0.1701 0.1741 0.1670
Sep 21, 2023 0.1689 -0.0178 -9.53% 0.1867 0.1867 0.1675
Sep 20, 2023 0.1843 -0.0202 -9.88% 0.2045 0.2045 0.1807
Sep 19, 2023 0.1980 0.0035 1.80% 0.1945 0.2280 0.1945
Sep 18, 2023 0.1841 -0.0019 -1.02% 0.1860 0.1878 0.1831
Sep 15, 2023 0.1816 -0.0044 -2.37% 0.1860 0.1876 0.1805
Sep 14, 2023 0.1848 -0.0012 -0.65% 0.1860 0.1921 0.1845
Sep 13, 2023 0.1885 0.0019 1.02% 0.1866 0.1948 0.1855
Sep 12, 2023 0.1878 -0.0004 -0.21% 0.1882 0.1933 0.1845
Sep 11, 2023 0.1880 -0.0022 -1.16% 0.1902 0.1941 0.1856
Sep 4, 2023 2.1500 0.0000 0.00% 2.1500 2.1500 2.1500
Aug 22, 2023 2.1500 0.0000 0.00% 2.1500 2.1500 2.1500
Aug 9, 2023 2.1500 0.0700 3.37% 2.0800 2.2400 2.0000
Aug 8, 2023 2.0400 0.1000 5.15% 1.9400 2.0700 1.8900

Galera Therapeutics, Inc. Events

Time (UTC) Country Event
Tuesday, November 7, 2023

Time (UTC)

13:30

Country

US

Event

Q3 2023 Galera Therapeutics Inc Earnings Release
Q3 2023 Galera Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Wednesday, March 6, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 Galera Therapeutics Inc Earnings Release
Q4 2023 Galera Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Total Operating Expense 51.226 73.368 70.553 50.691 24.255
Selling/General/Admin. Expenses, Total 20.214 20.951 15.708 8.358 5.592
Research & Development 31.012 52.417 54.845 42.333 18.663
Operating Income -51.226 -73.368 -70.553 -50.691 -24.255
Interest Income (Expense), Net Non-Operating -11.066 -7.166 -3.681 -1.248 0.356
Net Income Before Taxes -62.292 -80.534 -74.234 -51.939 -23.899
Net Income After Taxes -62.222 -80.534 -74.218 -51.93 -23.676
Net Income Before Extra. Items -62.222 -80.534 -74.218 -51.93 -23.676
Net Income -62.222 -80.534 -74.218 -51.93 -23.676
Total Adjustments to Net Income -7.176 -5.91
Income Available to Common Excl. Extra. Items -62.222 -80.534 -74.218 -59.106 -29.586
Income Available to Common Incl. Extra. Items -62.222 -80.534 -74.218 -59.106 -29.586
Diluted Net Income -62.222 -80.534 -74.218 -59.106 -29.586
Diluted Weighted Average Shares 27.0867 25.7895 24.8698 24.8116 24.3621
Diluted EPS Excluding Extraordinary Items -2.29715 -3.12275 -2.98427 -2.3822 -1.21443
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS -2.29715 -3.12275 -2.98427 -2.3822 -1.21443
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 16.807 13.881 13.158 12.959 11.929
Selling/General/Admin. Expenses, Total 9.246 6.609 5.021 4.853 5.293
Research & Development 7.561 7.272 8.137 8.106 6.636
Operating Income -16.807 -13.881 -13.158 -12.959 -11.929
Interest Income (Expense), Net Non-Operating -3.905 -3.829 -3.073 -3.075 -2.629
Net Income Before Taxes -20.712 -17.71 -16.258 -16.033 -14.558
Net Income After Taxes -20.712 -17.71 -16.188 -16.033 -14.558
Net Income Before Extra. Items -20.712 -17.71 -16.188 -16.033 -14.558
Net Income -20.712 -17.71 -16.188 -16.033 -14.558
Income Available to Common Excl. Extra. Items -20.712 -17.71 -16.188 -16.033 -14.558
Income Available to Common Incl. Extra. Items -20.712 -17.71 -16.188 -16.033 -14.558
Diluted Net Income -20.712 -17.71 -16.188 -16.033 -14.558
Diluted Weighted Average Shares 42.917 35.1961 27.9516 26.8235 26.8213
Diluted EPS Excluding Extraordinary Items -0.48261 -0.50318 -0.57914 -0.59772 -0.54278
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.48261 -0.50318 -0.57852 -0.59776 -0.54278
Gain (Loss) on Sale of Assets -0.027 0.001
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 38.535 77.392 77.929 117.57 83.852
Cash and Short Term Investments 31.597 71.217 72.776 112.29 81.517
Cash & Equivalents 4.266 19.859 15.872 18.356 14.811
Short Term Investments 27.331 51.358 56.904 93.934 66.706
Total Receivables, Net 0 0.87
Prepaid Expenses 3.646 6.175 5.153 5.28 1.465
Total Assets 44.036 83.311 84.098 123.376 88.056
Property/Plant/Equipment, Total - Net 0.481 0.823 1.553 1.749 0.568
Property/Plant/Equipment, Total - Gross 2.182 2.41 2.362 2.19 0.775
Accumulated Depreciation, Total -1.701 -1.587 -0.809 -0.441 -0.207
Goodwill, Net 0.881 0.881 0.881 0.881 0.881
Intangibles, Net 2.258 2.258 2.258 2.258 2.258
Other Long Term Assets, Total 1.881 1.957 1.477 0.918 0.497
Total Current Liabilities 13.379 12.935 13.968 9.694 6.444
Accounts Payable 3.581 5.044 5.146 3.945 3.867
Accrued Expenses 9.798 7.891 8.822 5.749 2.577
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 153.217 141.315 77.98 53.768 26.974
Total Long Term Debt 139.635 128.063 63.369 43.251 20.22
Long Term Debt 139.635 128.063 63.369 43.251 20.22
Deferred Income Tax 0.203 0.273 0.273 0.289 0.298
Other Liabilities, Total 0 0.044 0.37 0.534 0.012
Total Equity -109.181 -58.004 6.118 69.608 61.082
Redeemable Preferred Stock 0
Common Stock 0.028 0.026 0.025 0.025 0
Retained Earnings (Accumulated Deficit) -378.324 -316.102 -235.568 -161.35 -104.823
Other Equity, Total -0.022 -0.014 0.012 0.038 0.003
Total Liabilities & Shareholders’ Equity 44.036 83.311 84.098 123.376 88.056
Total Common Shares Outstanding 28.5101 26.4588 24.9761 24.8116 24.3621
Preferred Stock - Non Redeemable, Net 165.902
Additional Paid-In Capital 269.137 258.086 241.649 230.895
Other Current Assets, Total 3.292
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 54.243 38.535 44.917 55.188 65.276
Cash and Short Term Investments 47.751 31.597 42.769 52.007 60.947
Cash & Equivalents 25.687 4.266 12.73 17.376 19.645
Short Term Investments 22.064 27.331 30.039 34.631 41.302
Prepaid Expenses 3.2 3.646 2.098 3.181 4.329
Total Assets 59.714 44.036 50.713 61.078 71.099
Property/Plant/Equipment, Total - Net 0.418 0.481 0.57 0.654 0.738
Property/Plant/Equipment, Total - Gross 1.869 2.182 2.246 2.302 2.357
Accumulated Depreciation, Total -1.451 -1.701 -1.676 -1.648 -1.619
Goodwill, Net 0.881 0.881 0.881 0.881 0.881
Intangibles, Net 2.258 2.258 2.258 2.258 2.258
Other Long Term Assets, Total 1.914 1.881 2.087 2.097 1.946
Total Current Liabilities 13.266 13.379 11.632 10.986 10.931
Accounts Payable 5.937 3.581 3.591 3.588 4.131
Accrued Expenses 7.329 9.798 8.041 7.398 6.8
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 157.327 153.217 148.215 144.324 141.57
Total Long Term Debt 143.858 139.635 136.31 133.065 130.366
Long Term Debt 143.858 139.635 136.31 133.065 130.366
Deferred Income Tax 0.203 0.203 0.273 0.273 0.273
Other Liabilities, Total 0 0 0 0
Total Equity -97.613 -109.181 -97.502 -83.246 -70.471
Common Stock 0.043 0.028 0.027 0.027 0.027
Additional Paid-In Capital 298.362 269.137 264.7 262.94 261.108
Retained Earnings (Accumulated Deficit) -396.034 -378.324 -362.136 -346.103 -331.545
Other Equity, Total 0.016 -0.022 -0.093 -0.11 -0.061
Total Liabilities & Shareholders’ Equity 59.714 44.036 50.713 61.078 71.099
Total Common Shares Outstanding 42.9068 28.5101 26.4388 26.8216 26.8194
Total Receivables, Net
Redeemable Preferred Stock 0
Other Current Assets, Total 3.292 3.292 0.05
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -62.222 -80.534 -74.218 -51.93 -23.676
Cash From Operating Activities -43.426 -67.958 -59.537 -46.661 -22.166
Cash From Operating Activities 0.114 0.778 0.368 0.267 0.127
Deferred Taxes -0.07 0 -0.016 -0.009 -0.223
Non-Cash Items 15.493 14.425 10.416 5.666 1.083
Changes in Working Capital 3.259 -2.627 3.913 -0.655 0.523
Cash From Investing Activities 23.994 5.238 36.547 -27.825 -59.036
Capital Expenditures -0.025 -0.283 -0.457 -0.633 -0.347
Other Investing Cash Flow Items, Total 24.019 5.521 37.004 -27.192 -58.689
Cash From Financing Activities 3.889 66.707 20.506 78.031 89.844
Financing Cash Flow Items 0 69.844
Issuance (Retirement) of Debt, Net 0 57.5 20 20 20
Net Change in Cash -15.543 3.987 -2.484 3.545 8.642
Issuance (Retirement) of Stock, Net 3.889 9.207 0.506 58.031
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -17.71 -62.222 -46.034 -30.001 -15.443
Cash From Operating Activities -11.666 -43.426 -29.481 -20.271 -11.385
Cash From Operating Activities 0.02 0.114 0.088 0.061 0.031
Non-Cash Items 5.681 15.493 13.675 8.68 4.151
Changes in Working Capital 0.343 3.259 2.79 0.989 -0.124
Cash From Investing Activities 5.305 23.994 21.215 16.611 9.996
Capital Expenditures 0 -0.025 -0.025 -0.02 -0.013
Other Investing Cash Flow Items, Total 5.305 24.019 21.24 16.631 10.009
Cash From Financing Activities 27.782 3.889 1.187 1.177 1.175
Issuance (Retirement) of Stock, Net 27.782 3.889 1.187 1.177 1.175
Issuance (Retirement) of Debt, Net 0 0 0
Net Change in Cash 21.421 -15.543 -7.079 -2.483 -0.214
Deferred Taxes -0.07

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Galera Therapeutics, Inc. Company profile

About Galera Therapeutics Inc

Galera Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing and commercializing a pipeline of therapeutics to transform radiotherapy in cancer. The Company's lead product candidate, avasopasem manganese (GC4419), is a potent and selective small molecule dismutase mimetic, which is developed for the reduction of severe oral mucositis (SOM). It is also developing a second dismutase mimetic product candidate, GC4711, to increase the anti-cancer efficacy of stereotactic body radiation therapy (SBRT). It is evaluating GC4419 in a Phase III registrational trial (ROMAN trial) to reduce the incidence and severity of SOM induced by radiotherapy in patients with head and neck cancer (HNC), its lead indication. The Company is also evaluating GC4711 in combination with SBRT in a Phase I/II safety and anti-cancer efficacy trial in non-small cell lung cancer and a Phase IIb trial of GC4711 in combination with SBRT in patients with pancreatic cancer.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Galera Therapeutics Inc revenues was not reported. Net loss increased 9% to $80.5M. Higher net loss reflects General and administrative - Balancing increase of 32% to $16.6M (expense), Interest expense increase of 47% to $7.2M (expense), Stock-based Compensation in SGA increase of 40% to $4.3M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.98 to -$3.12.

Industry: Bio Therapeutic Drugs

45 Liberty Blvd.
Suite 230
MALVERN
PENNSYLVANIA 19355
US

Income Statement

  • Annual
  • Quarterly

News

How to Trade The Triple Top

Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

14:13, 27 September 2023
USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

People also watch

US100

14,839.50 Price
-0.100% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

XRP/USD

0.52 Price
-1.530% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

Gold

1,823.39 Price
-0.360% 1D Chg, %
Long position overnight fee -0.0196%
Short position overnight fee 0.0114%
Overnight fee time 21:00 (UTC)
Spread 0.30

BTC/USD

27,604.95 Price
-0.930% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading